GSK Expects To Launch Once-Daily HIV Combo Product Ahead Of Gilead
This article was originally published in The Pink Sheet Daily
Executive Summary
GlaxoSmithKline believes its future once-daily combination of Epivir and Ziagen will be stronger than Gilead's pending HIV combination